Literature DB >> 6491377

Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers.

P F Bonventre, C Linnemann, L S Weckbach, J L Staneck, C R Buncher, E Vigdorth, H Ritz, D Archer, B Smith.   

Abstract

Serum samples taken from women with toxic-shock syndrome (TSS) and from women without a history of TSS were examined for the presence of antibodies to toxic-shock-syndrome toxin (TST). Serum samples from 38 women with TSS and from 70 women with no history of TSS were analyzed by radioimmunoassay (RIA) and by an enzyme-linked immunoadsorbent assay (ELISA). Antitoxin titers obtained by the assays were highly correlated. Antibody levels in sera of women with TSS, or a history of TSS, were significantly lower than levels in sera of women with no prior evidence of TSS. The mean level of antitoxin titers in the total sample of acute, convalescent, and recovered TSS groups was significantly lower than that of the control groups, which consisted of 31 carriers of genital Staphylococcus aureus and a similar number of age- and race-matched noncarriers. Although a trend toward elevated antitoxin titers was apparent after recovery, no vigorous immunologic response to TST was noted. In contrast, the majority of healthy women demonstrated measurable antitoxin titers, a finding indicative of current or prior colonization with TST-producing strains of S. aureus. The data suggest that absence of antibodies to the TSS toxin may be a predisposing factor in the development of clinical disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6491377     DOI: 10.1093/infdis/150.5.662

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  High levels of antibody to panton-valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection.

Authors:  Christina R Hermos; Pauline Yoong; Gerald B Pier
Journal:  Clin Infect Dis       Date:  2010-10-14       Impact factor: 9.079

2.  A fatal case of staphylococcal toxic shock syndrome.

Authors:  Partha Roy; A K Sahni; Anshu Kumar
Journal:  Med J Armed Forces India       Date:  2013-08-02

3.  Determination by western blot (immunoblot) of seroconversions to toxic shock syndrome (TSS) toxin 1 and enterotoxin A, B, or C during infection with TSS- and non-TSS-associated Staphylococcus aureus.

Authors:  J L Whiting; P M Rosten; A W Chow
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

4.  [IgM antibodies to toxic shock syndrome toxin-1 in human sera and human immunoglobulins].

Authors:  N Dickgiesser; F Düzgün
Journal:  Klin Wochenschr       Date:  1988-01-04

5.  Imbalanced serum IgG subclass pattern in toxic shock syndrome patients: deficiency of specific IgG1 and IgG4 subclass antibodies to toxic shock syndrome toxin 1.

Authors:  B Christensson; P J Johansson; V A Oxelius
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

6.  [IgG antibodies against toxic shock syndrome toxin 1 in human immunoglobulins].

Authors:  N Dickgiesser; B Kustermann
Journal:  Klin Wochenschr       Date:  1986-07-15

7.  [IgG antibodies to toxic shock syndrome toxin-1 (TSST-1) in human sera].

Authors:  N Dickgiesser; B Kustermann
Journal:  Klin Wochenschr       Date:  1987-03-16

Review 8.  Toxic shock syndrome.

Authors:  J K Todd
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

9.  Staphylococcal superantigens and T cell expansions in Wegener's granulomatosis.

Authors:  E R Popa; C A Stegeman; N A Bos; C G M Kallenberg; J W Cohen Tervaert
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

10.  The effect of vaginal microbial communities on colonization by Staphylococcus aureus with the gene for toxic shock syndrome toxin 1 (TSST-1): a case-control study.

Authors:  Jacob D Pierson; Melanie A Hansmann; Catherine C Davis; Larry J Forney
Journal:  Pathog Dis       Date:  2018-06-01       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.